Results 131 to 140 of about 582,301 (339)

Short‐term actions of epigalocatechin‐3‐gallate in the liver: a mechanistic insight into hypoglycemic and potential toxic effects

open access: yesFEBS Open Bio, EarlyView.
Epigallocatechin‐3‐gallate (EGCG) acutely inhibited gluconeogenesis and enhanced glycolysis, glycogenolysis, and fatty acid oxidation in perfused rat livers. Mechanistic assays revealed mitochondrial uncoupling, inhibition of pyruvate carboxylation and glucose‐6‐phosphatase, shift of NADH/NAD+ ratios toward oxidation, and loss of membrane integrity ...
Carla Indianara Bonetti   +8 more
wiley   +1 more source

FACTORS GOVERNING THE EXCRETION RATE OF UREA

open access: hybrid, 1921
James H. Austin   +2 more
openalex   +1 more source

Association Between Urinary Sodium and Potassium Excretion and Blood Pressure Among Adults in the United States: National Health and Nutrition Examination Survey, 2014

open access: yesCirculation, 2018
S. Jackson   +10 more
semanticscholar   +1 more source

Structural and functional analysis of Bacillus sarcosine oxidase and its activity toward cyclic imino acids

open access: yesFEBS Open Bio, EarlyView.
Sarcosine oxidase from Bacillus sp. (SoxB) recognizes l‐proline (l‐Pro), d‐proline (d‐Pro), and l‐thioproline (l‐Tpr) as minor substrates. In this study, we measured their absorption spectra, determined the crystal structures of their enzyme complexes, and performed site‐directed mutagenesis of key residues.
Yuqi Zhang   +5 more
wiley   +1 more source

Pharmacokinetic drug-drug interaction and their implication in clinical management

open access: yesJournal of Research in Medical Sciences, 2013
Drug-drug interactions (DDIs) are one of the commonest causes of medication error in developed countries, particularly in the elderly due to poly-therapy, with a prevalence of 20-40%.
Palleria Caterina   +7 more
doaj  

Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans

open access: yesPharmacology Research & Perspectives
Aficamten, a cardiac myosin inhibitor, is being developed for the treatment of patients with symptomatic hypertrophic cardiomyopathy (HCM). The purpose of this study was to determine the absorption, metabolism, and excretion of aficamten.
Donghong Xu   +6 more
doaj   +1 more source

Urinary sodium and potassium excretion, mortality, and cardiovascular events.

open access: yesNew England Journal of Medicine, 2014
M. O’Donnell   +28 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy